Susan Elizabeth Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Susan Elizabeth Smith has a total of 366 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Sikora
University of Colorado School of Medicine, Department of Biomedical Informatics
50 shared publications - Brian Murray
University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences. Department of Clinical Pharmacy, Aurora, CO, USA
25 shared publications - Mojdeh Saba Heavner
University of Maryland School of Pharmacy Baltimore Maryland USA
15 shared publications - Christopher M. Bland
University of Georgia College of Pharmacy Savannah Georgia USA
13 shared publications - William Anthony Hawkins
Department of Clinical and Administrative Pharmacy University of Georgia College of Pharmacy Athens Georgia USA
13 shared publications - Xianyan Chen
University of Georgia College of Public Health, Department of Epidemiology & Biostatistics
13 shared publications
Latest Publications
- Open Access
- 8 November 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (11)
Association Between Medication‐Related Skin Punctures and Delirium in the ICU : An Exploratory Cohort Study
Background: Delirium is among the most common neurological complications in intensive care unit ( ICU ) patients, yet many medication‐related contributors remain poorly understood. As medication experts, pharmacists are uniquely positioned to lead efforts in identifying, mitigating, and preventing drug‐related risk factors for delirium. One underexplored risk factor is the frequency of medication‐related skin punctures. The purpose of this study was to evaluate the association between ICU delirium and the number of medication‐related skin punctures, with the goal of identifying potential pharmacist‐driven interventions to reduce delirium as well as improve patient experience and outcomes. Methods: This was a retrospective, observational, exploratory cohort study conducted in the ICU of a 384‐bed community hospital. Patients were divided into two groups, low‐punctures and high‐punctures, using the median number of skin punctures per day as the threshold for defining groups. The primary outcome was the incidence of delirium. Secondary outcomes were delirium‐free days, all‐cause mortality, hospital length of stay ( LOS ), and ICU LOS . Results: A total of 404 patients were included in this study. The median number of medication‐related skin punctures was 3.79 per day. There were 205 patients in the low‐punctures group (0 to less than 4 punctures per day) and 199 patients in the high‐punctures group (at least 4 punctures per day). The high‐punctures group was associated with increased odds of delirium (odds ratio [ OR ] 2.09, 95% confidence interval [ CI ] 1.22–3.58, p = 0.007). There was no significant difference in delirium‐free days, hospital LOS , and all‐cause mortality between groups; however, ICU LOS was significantly longer in the high‐punctures group (7 vs. 5 days, p < 0.001). Conclusion: The frequency of medication‐related skin punctures ICU patients received may be associated with an increased risk of delirium. These exploratory findings support future research evaluating the impact of pharmacist‐driven “skin puncture stewardship” on ICU delirium prevention, patient experience, and overall clinical outcomes.
- 8 November 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (11)
Open AccessAssociation Between Medication‐Related Skin Punctures and Delirium in the ICU : An Exploratory Cohort Study
Background: Delirium is among the most common neurological complications in intensive care unit ( ICU ) patients, yet many medication‐related contributors remain poorly understood. As medication experts, pharmacists are uniquely positioned to lead efforts in identifying, mitigating, and preventing drug‐related risk factors for delirium. One underexplored risk factor is the frequency of medication‐related skin punctures. The purpose of this study was to evaluate the association between ICU delirium and the number of medication‐related skin punctures, with the goal of identifying potential pharmacist‐driven interventions to reduce delirium as well as improve patient experience and outcomes. Methods: This was a retrospective, observational, exploratory cohort study conducted in the ICU of a 384‐bed community hospital. Patients were divided into two groups, low‐punctures and high‐punctures, using the median number of skin punctures per day as the threshold for defining groups. The primary outcome was the incidence of delirium. Secondary outcomes were delirium‐free days, all‐cause mortality, hospital length of stay ( LOS ), and ICU LOS . Results: A total of 404 patients were included in this study. The median number of medication‐related skin punctures was 3.79 per day. There were 205 patients in the low‐punctures group (0 to less than 4 punctures per day) and 199 patients in the high‐punctures group (at least 4 punctures per day). The high‐punctures group was associated with increased odds of delirium (odds ratio [ OR ] 2.09, 95% confidence interval [ CI ] 1.22–3.58, p = 0.007). There was no significant difference in delirium‐free days, hospital LOS , and all‐cause mortality between groups; however, ICU LOS was significantly longer in the high‐punctures group (7 vs. 5 days, p < 0.001). Conclusion: The frequency of medication‐related skin punctures ICU patients received may be associated with an increased risk of delirium. These exploratory findings support future research evaluating the impact of pharmacist‐driven “skin puncture stewardship” on ICU delirium prevention, patient experience, and overall clinical outcomes.
- Open Access
Pharmacist-Led Comprehensive Medication Management and Patient Outcomes in Pediatric Intensive Care Unit Patients: A Multicenter Cohort Study
Objective: Clinical pharmacists improve medication management and safety in intensive care units, yet their role in neonatal and pediatric intensive care remains highly variable across institutions. Evidence supporting standardized clinical pharmacy practice models in these settings is limited. This study evaluated the association between pharmacist service coverage and clinical outcomes in critically ill pediatric patients. Design: Multicenter, observational study with prospective and retrospective data collection. Setting: ICUs at participating institutions in the United States and internationally. Patients: Patients <18 years of age Intervention: None Measurements: The primary exposure was pharmacist-led comprehensive medication management (CMM) with daily participation in multidisciplinary rounds. The secondary exposure was the pharmacist-to-ICU-patient ratio. The primary outcome was hazard of discharge alive (HDA) from the ICU. Secondary outcomes included in-hospital mortality, hospital HDA, and hazard of extubation alive (HEA). Fine-Gray competing risks models and multivariable Firth logistic regression were used for adjusted analyses. Main results: A total of 1,459 patients cared for by 69 clinical pharmacists across 31 institutions were included. Daily CMM with rounding was associated with a higher HDA from the ICU (HR 2.60, 95% CI 2.17-3.10; p<0.001), higher HDA from the hospital (HR 2.25, 95% CI 1.83-2.75; p<0.001), and a higher HEA (HR 1.21, 95% CI 1.10-1.33; p<0.001), but not with in-hospital mortality (OR 0.44, 95% CI 0.14-1.36; p=0.154). The pharmacist-to-ICU-patient ratio was not significantly associated with ICU HDA (HR 1.00, 95% CI 0.99-1.01; p=0.88) or any secondary outcome. Conclusions: Daily pharmacist-provided CMM with multidisciplinary ICU rounding was associated with improved discharge outcomes among critically ill pediatric and neonatal patients, whereas pharmacist-to-ICU-patient ratio alone was not. These findings support standardized integration of clinical pharmacists into daily multidisciplinary rounds in this setting.
Open AccessPharmacist-Led Comprehensive Medication Management and Patient Outcomes in Pediatric Intensive Care Unit Patients: A Multicenter Cohort Study
Objective: Clinical pharmacists improve medication management and safety in intensive care units, yet their role in neonatal and pediatric intensive care remains highly variable across institutions. Evidence supporting standardized clinical pharmacy practice models in these settings is limited. This study evaluated the association between pharmacist service coverage and clinical outcomes in critically ill pediatric patients. Design: Multicenter, observational study with prospective and retrospective data collection. Setting: ICUs at participating institutions in the United States and internationally. Patients: Patients <18 years of age Intervention: None Measurements: The primary exposure was pharmacist-led comprehensive medication management (CMM) with daily participation in multidisciplinary rounds. The secondary exposure was the pharmacist-to-ICU-patient ratio. The primary outcome was hazard of discharge alive (HDA) from the ICU. Secondary outcomes included in-hospital mortality, hospital HDA, and hazard of extubation alive (HEA). Fine-Gray competing risks models and multivariable Firth logistic regression were used for adjusted analyses. Main results: A total of 1,459 patients cared for by 69 clinical pharmacists across 31 institutions were included. Daily CMM with rounding was associated with a higher HDA from the ICU (HR 2.60, 95% CI 2.17-3.10; p<0.001), higher HDA from the hospital (HR 2.25, 95% CI 1.83-2.75; p<0.001), and a higher HEA (HR 1.21, 95% CI 1.10-1.33; p<0.001), but not with in-hospital mortality (OR 0.44, 95% CI 0.14-1.36; p=0.154). The pharmacist-to-ICU-patient ratio was not significantly associated with ICU HDA (HR 1.00, 95% CI 0.99-1.01; p=0.88) or any secondary outcome. Conclusions: Daily pharmacist-provided CMM with multidisciplinary ICU rounding was associated with improved discharge outcomes among critically ill pediatric and neonatal patients, whereas pharmacist-to-ICU-patient ratio alone was not. These findings support standardized integration of clinical pharmacists into daily multidisciplinary rounds in this setting.
- 10 September 2026
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
Performance evaluation of a large language model for medication management tasks
Purpose: Large language models (LLMs) have proven performance for certain diagnostic tasks; however, limited studies have evaluated their consistency in recommending appropriate medication regimens for a given diagnosis. Medication management is a complex task that requires synthesis of drug formulation and complete order instructions for safe use. Here, the performance of GPT-4o, an LLM available with OpenAI’s ChatGPT, was tested on 3 medication management tasks. Methods: GPT-4o performance was tested on 3 medication tasks: identifying available formulations for a given generic drug name, identifying drug-drug interactions (DDIs) for a given medication regimen, and preparing a medication order for a given generic drug name. For each experiment, the model’s raw text response was captured exactly as returned and evaluated using clinician evaluation in addition to standard LLM metrics, including Term Frequency-Inverse Document Frequency (TF-IDF) vectors, normalized Levenshtein similarity, and Recall-Oriented Understudy for Gisting Evaluation (ROUGE-1/ROUGE-L) F1 score between each response and its reference string. Results: For the first task of drug-formulation matching, GPT-4o had 49% accuracy for generic medications being matched to all available formulations, with an average of 1.23 omissions per medication and 1.14 hallucinations per medication. For the second task of drug-drug interaction identification, the accuracy was 54.7% for identifying the DDI pair. For the third task, GPT-4o generated order sentences containing no medication or abbreviation errors in 65.8% of the cases. Conclusion: Model performance for basic medication tasks was consistently poor. This evaluation highlights the need for domain-specific training through clinician-annotated datasets and a comprehensive evaluation framework for benchmarking performance.
- 10 September 2026
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
Performance evaluation of a large language model for medication management tasks
Purpose: Large language models (LLMs) have proven performance for certain diagnostic tasks; however, limited studies have evaluated their consistency in recommending appropriate medication regimens for a given diagnosis. Medication management is a complex task that requires synthesis of drug formulation and complete order instructions for safe use. Here, the performance of GPT-4o, an LLM available with OpenAI’s ChatGPT, was tested on 3 medication management tasks. Methods: GPT-4o performance was tested on 3 medication tasks: identifying available formulations for a given generic drug name, identifying drug-drug interactions (DDIs) for a given medication regimen, and preparing a medication order for a given generic drug name. For each experiment, the model’s raw text response was captured exactly as returned and evaluated using clinician evaluation in addition to standard LLM metrics, including Term Frequency-Inverse Document Frequency (TF-IDF) vectors, normalized Levenshtein similarity, and Recall-Oriented Understudy for Gisting Evaluation (ROUGE-1/ROUGE-L) F1 score between each response and its reference string. Results: For the first task of drug-formulation matching, GPT-4o had 49% accuracy for generic medications being matched to all available formulations, with an average of 1.23 omissions per medication and 1.14 hallucinations per medication. For the second task of drug-drug interaction identification, the accuracy was 54.7% for identifying the DDI pair. For the third task, GPT-4o generated order sentences containing no medication or abbreviation errors in 65.8% of the cases. Conclusion: Model performance for basic medication tasks was consistently poor. This evaluation highlights the need for domain-specific training through clinician-annotated datasets and a comprehensive evaluation framework for benchmarking performance.
- Open Access
- 4 September 2026
- Published by F1000 Research Ltd in MedEdPublish
- Vol. 16, 47
Outcomes of a Multi-campus, Multi-semester Applied Critical Care Research Elective
Objective The Research in Critical Care Pharmacotherapy elective implemented a novel approach that promoted collaborative research across four campuses for up to four semesters of credit. The impact of a multi-semester research elective on pharmacy student confidence and experience are unknown. Methods Retrospective evaluation over five years of a multi-campus, multi-semester research elective course in a traditional Doctor of Pharmacy program. A survey was developed to assess confidence in research skills and was distributed at the start of the elective and after the final semester of course completion. Confidence was measured using the Dreyfus model. The primary outcome was median student confidence of overall research and secondary outcomes included median confidence and frequency of research experience encountered in the elective course in 20 specific areas of research. Results 47 students were assessed over 5 years of the course offering. 45 of the 47 students responded to the pre-course survey and 43 students responded to the post-course survey. There was a statistically significant improvement in confidence in 17 of the 19 research categories assessed. More than 40% of students gained experience in 12 of the 20 total research areas offered. Conclusion A multi-semester research elective improves confidence in most research skills and gives students a breadth of experiences across the research process.
- 4 September 2026
- Published by F1000 Research Ltd in MedEdPublish
- Vol. 16, 47
Open AccessOutcomes of a Multi-campus, Multi-semester Applied Critical Care Research Elective
Objective The Research in Critical Care Pharmacotherapy elective implemented a novel approach that promoted collaborative research across four campuses for up to four semesters of credit. The impact of a multi-semester research elective on pharmacy student confidence and experience are unknown. Methods Retrospective evaluation over five years of a multi-campus, multi-semester research elective course in a traditional Doctor of Pharmacy program. A survey was developed to assess confidence in research skills and was distributed at the start of the elective and after the final semester of course completion. Confidence was measured using the Dreyfus model. The primary outcome was median student confidence of overall research and secondary outcomes included median confidence and frequency of research experience encountered in the elective course in 20 specific areas of research. Results 47 students were assessed over 5 years of the course offering. 45 of the 47 students responded to the pre-course survey and 43 students responded to the post-course survey. There was a statistically significant improvement in confidence in 17 of the 19 research categories assessed. More than 40% of students gained experience in 12 of the 20 total research areas offered. Conclusion A multi-semester research elective improves confidence in most research skills and gives students a breadth of experiences across the research process.
- Open Access
Impact of Early Interprofessional Involvement with a Critical Care Pharmacist on Patient Outcomes in the Intensive Care Unit
Background: While critical care pharmacists (CCPs) are broadly associated with improvements in outcomes for critically ill patients, operationalizing staffing in the intensive care unit (ICU) requires further study. The purpose of this evaluation was to determine the relationship of a CCP on interprofessional rounds for weekday admissions of ICU patients on patient-centered outcomes. Methods: This post-hoc analysis of the Optimizing Pharmacist-Team Integration for ICU Patient Management (OPTIM) study included adults admitted to an ICU on a weekday in the multicenter observational study. The primary outcome was in-hospital mortality. The primary exposure was level of comprehensive medication management (CMM) during the first 24 hours of ICU stay. A secondary exposure was pharmacist-to-patient ratio. Multivariable generalized estimating equations (GEE) were used to estimate associations between mortality and patient, ICU, and institution variables. Fine-Gray sub-distribution hazards regression estimated hazard of discharge alive (HDA) from the ICU and hospital and hazard of extubation alive. Results: 21,835 patients met inclusion criteria, and 76.1% of patients had CMM delivered on interprofessional rounds. Patients who had no CMM on the first ICU day had an increased risk of mortality of 23% (Odds Ratio (OR) 1.23, 95% Confidence Interval (CI) 1.04-1.46, p=0.02) compared to those who received CMM on interprofessional rounds. Patients with no CMM also had decreased HDA from the ICU and hospital and decreased hazard of extubation alive. No difference was seen in any outcomes when comparing other levels of CMM (CMM delivered outside of interprofessional rounds or abbreviated CMM) compared to CMM delivered on rounds. Conclusions: Absence of pharmacist CMM on the first day of ICU stay for patients with weekday admission was associated with an increased risk of in-hospital mortality, but no difference was seen across levels of CMM: this signal supports further investigation in prospective analysis. Key Points: Question: Do ICU patients who do not receive comprehensive medication management (CMM) from a critical care pharmacist (CCP) on interprofessional rounds on the first day have a relationship with worse outcomes? Finding: Patients not receiving CMM had increased mortality and length of stay, but no difference in outcomes was observed in patients receiving partial CMM or CMM delivered outside of interprofessional rounds. Meaning: CMM from a CCP is associated with improved patient outcomes compared to those not receiving CMM, but further research is needed to clarify optimal delivery of CMM and the impact of CCP participation on interprofessional rounds.
Open AccessImpact of Early Interprofessional Involvement with a Critical Care Pharmacist on Patient Outcomes in the Intensive Care Unit
Background: While critical care pharmacists (CCPs) are broadly associated with improvements in outcomes for critically ill patients, operationalizing staffing in the intensive care unit (ICU) requires further study. The purpose of this evaluation was to determine the relationship of a CCP on interprofessional rounds for weekday admissions of ICU patients on patient-centered outcomes. Methods: This post-hoc analysis of the Optimizing Pharmacist-Team Integration for ICU Patient Management (OPTIM) study included adults admitted to an ICU on a weekday in the multicenter observational study. The primary outcome was in-hospital mortality. The primary exposure was level of comprehensive medication management (CMM) during the first 24 hours of ICU stay. A secondary exposure was pharmacist-to-patient ratio. Multivariable generalized estimating equations (GEE) were used to estimate associations between mortality and patient, ICU, and institution variables. Fine-Gray sub-distribution hazards regression estimated hazard of discharge alive (HDA) from the ICU and hospital and hazard of extubation alive. Results: 21,835 patients met inclusion criteria, and 76.1% of patients had CMM delivered on interprofessional rounds. Patients who had no CMM on the first ICU day had an increased risk of mortality of 23% (Odds Ratio (OR) 1.23, 95% Confidence Interval (CI) 1.04-1.46, p=0.02) compared to those who received CMM on interprofessional rounds. Patients with no CMM also had decreased HDA from the ICU and hospital and decreased hazard of extubation alive. No difference was seen in any outcomes when comparing other levels of CMM (CMM delivered outside of interprofessional rounds or abbreviated CMM) compared to CMM delivered on rounds. Conclusions: Absence of pharmacist CMM on the first day of ICU stay for patients with weekday admission was associated with an increased risk of in-hospital mortality, but no difference was seen across levels of CMM: this signal supports further investigation in prospective analysis. Key Points: Question: Do ICU patients who do not receive comprehensive medication management (CMM) from a critical care pharmacist (CCP) on interprofessional rounds on the first day have a relationship with worse outcomes? Finding: Patients not receiving CMM had increased mortality and length of stay, but no difference in outcomes was observed in patients receiving partial CMM or CMM delivered outside of interprofessional rounds. Meaning: CMM from a CCP is associated with improved patient outcomes compared to those not receiving CMM, but further research is needed to clarify optimal delivery of CMM and the impact of CCP participation on interprofessional rounds.
- 10 July 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (8) , e70185
A Data‐Driven Medication Regimen Complexity Score for Critically Ill Patients: MRC ‐ ICU 2.0
Background: The 2019 medication regimen complexity‐intensive care unit (MRC‐ICU) score is associated with patient outcomes, ICU complications, and critical care pharmacist workload. This score was developed using heuristic component selection and validated in a single‐center cohort of 130 ICU patients. We sought to apply data‐driven reweighting methodology in a large, multicenter cohort of ICU adults to improve the predictive capabilities of MRC‐ICU. Methods: This was a retrospective, observational cohort study of adults admitted to an ICU between 2015 and 2023 at two academic health systems. Machine learning–based methods, including Principal Component Analysis and Random Forest, were used to create an updated MRC‐ICU score optimized to predict three outcomes: hospital mortality, ICU fluid overload (FO) occurrence, and invasive mechanical ventilation (IMV) use. MRC‐ICU 2.1 used average mortality, FO, and IMV use; MRC‐ICU 2.2 used average mortality and FO and adjusted for prolonged IMV use. Data from one center were used for training and testing, and data from the other for validation. The predictive abilities of MRC‐ICU 2.1 and 2.2 for each outcome were compared to MRC‐ICU 1.0 and to severity of illness scores (i.e., Acute Physiology and Chronic Health Evaluation [APACHE] II and Sequential Organ Failure Assessment [SOFA]). Results: A total of 19,117 patients across training, testing, and validation datasets were included. MRC‐ICU 2.0 scores outperformed MRC‐ICU 1.0 for predicting most outcomes, with improvements in Area Under the Receiver Operating Characteristic (AUROC) ranging from +0.03 to +0.08 across datasets. MRC‐ICU 2.1 and 2.2 did not consistently outperform APACHE II and SOFA in predicting mortality. The addition of MRC‐ICU 2.0 scores to models including APACHE II or SOFA resulted in statistically significant improvements in discrimination in several settings (DeLong p < 0.05), with AUROC increases generally ranging from approximately +0.01 to +0.13 depending on outcome and dataset. Conclusions: The updated MRC‐ICU 2.0 score (MRC‐ICU 2.1 and 2.2) demonstrated consistently improved discrimination compared with the original MRC‐ICU 1.0 across outcomes and datasets. The performance of MRC‐ICU 2.0 (MRC‐ICU 2.1 and 2.2) was generally comparable to established severity‐of‐illness scores (SOFA and APACHE II), although it did not consistently outperform these measures. When incorporated into combined models, MRC‐ICU 2.0 provided additional predictive value, indicating that it captures information complementary to traditional severity‐of‐illness scores. Overall, these findings suggest that MRC‐ICU 2.0 represents an improved and clinically interpretable measure of medication regimen complexity that is useful as a complementary predictor.
- 10 July 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (8) , e70185
A Data‐Driven Medication Regimen Complexity Score for Critically Ill Patients: MRC ‐ ICU 2.0
Background: The 2019 medication regimen complexity‐intensive care unit (MRC‐ICU) score is associated with patient outcomes, ICU complications, and critical care pharmacist workload. This score was developed using heuristic component selection and validated in a single‐center cohort of 130 ICU patients. We sought to apply data‐driven reweighting methodology in a large, multicenter cohort of ICU adults to improve the predictive capabilities of MRC‐ICU. Methods: This was a retrospective, observational cohort study of adults admitted to an ICU between 2015 and 2023 at two academic health systems. Machine learning–based methods, including Principal Component Analysis and Random Forest, were used to create an updated MRC‐ICU score optimized to predict three outcomes: hospital mortality, ICU fluid overload (FO) occurrence, and invasive mechanical ventilation (IMV) use. MRC‐ICU 2.1 used average mortality, FO, and IMV use; MRC‐ICU 2.2 used average mortality and FO and adjusted for prolonged IMV use. Data from one center were used for training and testing, and data from the other for validation. The predictive abilities of MRC‐ICU 2.1 and 2.2 for each outcome were compared to MRC‐ICU 1.0 and to severity of illness scores (i.e., Acute Physiology and Chronic Health Evaluation [APACHE] II and Sequential Organ Failure Assessment [SOFA]). Results: A total of 19,117 patients across training, testing, and validation datasets were included. MRC‐ICU 2.0 scores outperformed MRC‐ICU 1.0 for predicting most outcomes, with improvements in Area Under the Receiver Operating Characteristic (AUROC) ranging from +0.03 to +0.08 across datasets. MRC‐ICU 2.1 and 2.2 did not consistently outperform APACHE II and SOFA in predicting mortality. The addition of MRC‐ICU 2.0 scores to models including APACHE II or SOFA resulted in statistically significant improvements in discrimination in several settings (DeLong p < 0.05), with AUROC increases generally ranging from approximately +0.01 to +0.13 depending on outcome and dataset. Conclusions: The updated MRC‐ICU 2.0 score (MRC‐ICU 2.1 and 2.2) demonstrated consistently improved discrimination compared with the original MRC‐ICU 1.0 across outcomes and datasets. The performance of MRC‐ICU 2.0 (MRC‐ICU 2.1 and 2.2) was generally comparable to established severity‐of‐illness scores (SOFA and APACHE II), although it did not consistently outperform these measures. When incorporated into combined models, MRC‐ICU 2.0 provided additional predictive value, indicating that it captures information complementary to traditional severity‐of‐illness scores. Overall, these findings suggest that MRC‐ICU 2.0 represents an improved and clinically interpretable measure of medication regimen complexity that is useful as a complementary predictor.
- Open Access
- 7 July 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (7) , e70258
Impact of Pharmacist Board Certification on Health Outcomes of Critically Ill Patients: An Analysis of the Optimizing Pharmacist‐Team Integration for ICU Patient Management ( OPTIM ) Study
Background: Critical care pharmacists (CCPs) reduce adverse drug events (ADEs) and mortality in the intensive care unit (ICU). Board certification is the established professional standard for CCPs, but its impact on ICU patient outcomes, including its relationship between CCP characteristics and workload, remains unclear. The purpose of this study was to evaluate the association between pharmacist board certification, CCP workload characteristics, and patient outcomes. Methods: This was a pre‐planned analysis of the multicenter, observational Optimizing Pharmacist‐Team Integration for ICU Patient Management (OPTIM) study including adult ICU patients cared for by CCPs. Patients cared for exclusively by board‐certified pharmacists on every ICU day were categorized as the BCP group; those with at least 1 day of care from a non‐board‐certified pharmacist comprised the non‐BCP group. The primary outcome was hospital mortality; secondary outcomes included the hazard of discharge alive (HDA) from the ICU and hospital. Multivariable logistic regression was used to evaluate the association between BCP and mortality; Fine‐Gray competing risk models were used to assess the relationship between BCP and ICU and hospital HDA. Results: In total, 201 pharmacists (184 BCPs; 17 non‐BCPs) from 63 institutions caring for 20 537 ICU patients were included. Care provided exclusively by a BCP (vs ≥ 1 day by a non‐BCP) was associated with lower mortality (odds ratio [OR] 0.80, 95% confidence interval [CI] 0.69–0.92, p = 0.002) and both a higher ICU HDA (hazard ratio [HR] 1.08, 95% CI 1.03–1.13, p < 0.001) and hospital HDA (HR 1.19, 95% CI 1.13–1.26, p < 0.001). Conclusion: Daily ICU care delivered by pharmacists with board certification was independently associated with reduced mortality and improved HDA from the ICU. Board‐certified pharmacists may enhance the quality and/or efficiency of critical care pharmacy services. These findings support the role of board certification as a modifiable factor to improve patient outcomes and optimize workload in the ICU.
- 7 July 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (7) , e70258
Open AccessImpact of Pharmacist Board Certification on Health Outcomes of Critically Ill Patients: An Analysis of the Optimizing Pharmacist‐Team Integration for ICU Patient Management ( OPTIM ) Study
Background: Critical care pharmacists (CCPs) reduce adverse drug events (ADEs) and mortality in the intensive care unit (ICU). Board certification is the established professional standard for CCPs, but its impact on ICU patient outcomes, including its relationship between CCP characteristics and workload, remains unclear. The purpose of this study was to evaluate the association between pharmacist board certification, CCP workload characteristics, and patient outcomes. Methods: This was a pre‐planned analysis of the multicenter, observational Optimizing Pharmacist‐Team Integration for ICU Patient Management (OPTIM) study including adult ICU patients cared for by CCPs. Patients cared for exclusively by board‐certified pharmacists on every ICU day were categorized as the BCP group; those with at least 1 day of care from a non‐board‐certified pharmacist comprised the non‐BCP group. The primary outcome was hospital mortality; secondary outcomes included the hazard of discharge alive (HDA) from the ICU and hospital. Multivariable logistic regression was used to evaluate the association between BCP and mortality; Fine‐Gray competing risk models were used to assess the relationship between BCP and ICU and hospital HDA. Results: In total, 201 pharmacists (184 BCPs; 17 non‐BCPs) from 63 institutions caring for 20 537 ICU patients were included. Care provided exclusively by a BCP (vs ≥ 1 day by a non‐BCP) was associated with lower mortality (odds ratio [OR] 0.80, 95% confidence interval [CI] 0.69–0.92, p = 0.002) and both a higher ICU HDA (hazard ratio [HR] 1.08, 95% CI 1.03–1.13, p < 0.001) and hospital HDA (HR 1.19, 95% CI 1.13–1.26, p < 0.001). Conclusion: Daily ICU care delivered by pharmacists with board certification was independently associated with reduced mortality and improved HDA from the ICU. Board‐certified pharmacists may enhance the quality and/or efficiency of critical care pharmacy services. These findings support the role of board certification as a modifiable factor to improve patient outcomes and optimize workload in the ICU.
- 6 July 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (7) , e70187
Response to Comment on “Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis”
- 6 July 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (7) , e70187
Response to Comment on “Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis”
- 30 June 2026
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 90 (9) , 102039
FLEXIBLE WORK ARRANGEMENTS IN PHARMACY ACADEMIA - AN OVERDUE IMPERATIVE
- 30 June 2026
- Published by Elsevier in American Journal of Pharmaceutical Education
- Vol. 90 (9) , 102039
FLEXIBLE WORK ARRANGEMENTS IN PHARMACY ACADEMIA - AN OVERDUE IMPERATIVE